Selection of an adjuvant for vaccination with the malaria antigen, MSA-2

Pye, David; Vandenberg, Kirsten; Dyer, Shanny L.; Irving, David O.; Goss, Neil H.; Woodrow, Graeme; Saul, Allan; Alving, Carl R.; Richards, Roberta L.; Ballou, W. Ripley; Wu, Min; Skoff, K; Anders, Robin F.

doi:10.1016/s0264-410x(96)00289-7

Cited by 28 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adjuvants improve the immunogenicity of antigens and can enhance the function of antigen presenting cells by enhancing systemic immune responses and influencing T-helper cell polarization creating bias towards Th1 or Th2 immune responses (Baldridge et al, 2000; Guy, 2007; McKee et al, 2010). The QS-21 and Montanide™ ISA720 adjuvants have shown to stimulate strong humoral and cellular responses (Kensil and Kammer, 1998; Kensil et al, 1991; Kensil et al, 1998; Pye et al, 1997). Both, adjuvants have been tested in human vaccines against malaria and viral diseases (Hui and Hashimoto, 2008; Mbawuike et al, 2007; Toledo et al, 2001; Vandepapeliere et al, 2008; Xue et al, 2010) but to our knowledge, these adjuvants have not been yet assayed in vaccines against parasitic helminths.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant-enhanced antibody and cellular responses to inclusion bodies expressing FhSAP2 correlates with protection of mice to Fasciola hepatica

Rivera

Espino

2016

Experimental Parasitology

View full text Add to dashboard Cite

Fasciola hepatica saposin-like protein-2 (FhSAP2) is a protein differentially expressed in various developmental stages of F. hepatica. Recombinant FhSAP2 has demonstrated the induction of partial protection in mice and rabbits when it is administered subcutaneously (SC) in Freund’s adjuvant. Because FhSAP2 is overexpressed in bacteria in the form of inclusion bodies (IBs), we isolated IBs expressing FhSAP2 and tested their immunogenicity when administered SC in mice emulsified in two different adjuvants: QS-21 and Montanide™ ISA720. Animals received three injections containing 20μg of protein two weeks apart and 4 weeks after the third injection, mice were infected with 10 F. hepatica metacercariae by oral route. The percentages of protection induced by FhSAP2-IBs were estimated to be between 60.0–62.5% when compared with adjuvant-vaccinated, infected controls. By determining the levels of IgG1 and IgG2a antibodies and IL-4 and IFNγ cytokines in the serum of experimental animals, it was found that both Th1 and Th2 immune responses were significantly increased in the FhSAP2-IBs vaccinated groups compared with the adjuvant-vaccinated, infected control groups. The adjuvant-vaccinated groups had significantly lower IgG1 to IgG2a ratios and lower IL-4 to IFNγ ratios than the FhSAP2-IBs vaccinated animals, which is indicative of higher levels of Th2 immune responses. Irrespective to the adjuvant used, animals vaccinated with FhSAP2-IBs exhibited significantly higher survival percentage and less liver damage than the adjuvant-control groups. This study suggests that FhSAP2 has potential as vaccine against F. hepatica and that the protection elicited by this molecule could be linked to a mechanism driven by the CD4-Th1 cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjuvant-enhanced antibody and cellular responses to inclusion bodies expressing FhSAP2 correlates with protection of mice to Fasciola hepatica

Rivera

Espino

2016

Experimental Parasitology

View full text Add to dashboard Cite

show abstract

“…Montanide ISA 720 is (SEPPIC, Paris, France) composed of natural metabolizable oil and highly refined emulsifier from mono-oleat.e family which forms a stable w/o emulsion. Its use with several recombinant malaria proteins has resulted in high antibody levels in mice, rabbits and sheep (77). Also it was used in a challenge trial with Saimiri monkeys which were vaccinated with P. fragile malarial antigen AMA-1.…”

Section: Montanide Isa720mentioning

confidence: 99%

New age adjuvants and delivery systems for subunit vaccines

Koduri

Manocha

Sabhnani

et al. 2000

Indian J Clin Biochem

View full text Add to dashboard Cite

The dramatic advancements in the field of vaccinology has led to the formulation of chemically well defined vaccines composed of synthetic peptides and recombinant proteins derived from the immunologically dominant regions of the pathogens. Though these subunit vaccines are safer compared to the traditional vaccines they are known to be poorly immunogenic. This necessitates the use of adjuvants to enhance the immunogenicity of these vaccine formulations. The most common adjuvant for human use is alum. Research in the past has focused on the development of systemic immunity using conventional immunization protocols. In the present era, the emphasis is on the development and formulation of alternative adjuvants and delivery systems in generating systemic as well as mucosal immunity. This review mainly focuses on a variety of adjuvants (particulate as well as non-particulate) used with protective antigens of HIV, malaria, plague, leprosy using modified delivery vehicles. The experience of our laboratory and other researchers in this field clearly proves that these new age adjuvants and delivery systems undoubtedly generate enhanced immune response -both humoral and cell mediated. The choice of antigens, the nature of adjuvant used and the mode of delivery employed have a profound effect on the type of immune response generated. Besides the quantity, the quality of the antibodies generated also play a vital role in protection against these diseases. Some of the adjuvants and delivery systems used promoted high titre and affinity antibodies, which were shown to be cytophilic in nature, an important criteria in providing protection to the host. Thus the studies on these adjuvants/ delivery systems with respect to various infectious diseases indicate their active role in efficient modulation of immune response along with safety and permissiblity.

show abstract

“…These adjuvants were selected because they form stable water-in-oil emulsions and induced high antibody levels that lasted for up to 1 year in mice, rabbits, and monkeys in previous studies using recombinant malaria proteins. 23,[26][27][28][29][30][31][32] More recently, a recombinant P. vivax CS protein produced in Escherichia coli and formulated in Montanide ISA 720 showed to be highly immunogenic in mice. 33 Several phase I clinical trials have been conducted using different malaria vaccine antigens in which these two adjuvants have been able to stimulate both humoral and cellular immune responses.…”

Section: Introductionmentioning

confidence: 99%